Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1999 | 1 |
2002 | 1 |
2019 | 2 |
2020 | 1 |
2021 | 2 |
2022 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
NPJ Breast Cancer. 2022 Apr 7;8(1):45. doi: 10.1038/s41523-022-00406-0.
NPJ Breast Cancer. 2022.
PMID: 35393425
Free PMC article.
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease.
Khanna D, Tashkin DP, Wells AU, Seibold JR, Wax S, Vazquez-Mateo C, Fleuranceau-Morel P, Damian D, Denton CP.
Khanna D, et al. Among authors: fleuranceau morel p.
J Rheumatol. 2021 Aug;48(8):1295-1298. doi: 10.3899/jrheum.191365. Epub 2020 Oct 1.
J Rheumatol. 2021.
PMID: 33004536
Clinical Trial.
Item in Clipboard
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Plummer R, Dean E, Arkenau HT, Redfern C, Spira AI, Melear JM, Chung KY, Ferrer-Playan J, Goddemeier T, Locatelli G, Dong J, Fleuranceau-Morel P, Diaz-Padilla I, Shapiro GI.
Plummer R, et al. Among authors: fleuranceau morel p.
Lung Cancer. 2022 Jan;163:19-26. doi: 10.1016/j.lungcan.2021.11.011. Epub 2021 Dec 1.
Lung Cancer. 2022.
PMID: 34894455
Free article.
Clinical Trial.
Item in Clipboard
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme.
Gordon C, Bassi R, Chang P, Kao A, Jayne D, Wofsy D, Fleuranceau-Morel P.
Gordon C, et al. Among authors: fleuranceau morel p.
Rheumatol Adv Pract. 2019 Aug 6;3(2):rkz021. doi: 10.1093/rap/rkz021. eCollection 2019.
Rheumatol Adv Pract. 2019.
PMID: 31528843
Free PMC article.
Item in Clipboard
Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial.
Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, Reinstrup Bihlet A, Byrjalsen I, Ragnar Andersen J, Eckstein F.
Hochberg MC, et al. Among authors: fleuranceau morel p.
JAMA. 2019 Oct 8;322(14):1360-1370. doi: 10.1001/jama.2019.14735.
JAMA. 2019.
PMID: 31593273
Free PMC article.
Clinical Trial.
Item in Clipboard
How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P.
Fleuranceau-Morel P.
Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):37-44. doi: 10.1002/pds.650.
Pharmacoepidemiol Drug Saf. 2002.
PMID: 11998550
Item in Clipboard
Origin of 4-hydroxynonenal incubation-induced inhibition of dopamine transporter and Na+/K+ adenosine triphosphate in rat striatal synaptosomes.
Fleuranceau-Morel P, Barrier L, Fauconneau B, Piriou A, Huguet F.
Fleuranceau-Morel P, et al.
Neurosci Lett. 1999 Dec 24;277(2):91-4. doi: 10.1016/s0304-3940(99)00652-7.
Neurosci Lett. 1999.
PMID: 10624817
Item in Clipboard
Cite
Cite